Spotlight on allogeneic CAR-T

CAR-T therapy involves utilizing a patient’s own T-cells to treat cancer and, as a technique, has rapidly expanded over the past year. However, obtaining patient samples can be problematic, time-consuming and costly. To make the use of the economy-of-scale, there has been a move away from autologous therapies to allogeneic therapies, which could be used ‘off-the-shelf’, although that transition is still in its early days.


This Spotlight will aim to review the advances in CAR-T therapy, the challenges the treatment has faced and the future as we advance allogeneic alternatives. In association with CellGenix GmbH and Lonza Pharma & Biotech.

Latest Content

See the latest content written by our experts